iShares Biotechnology ETF
NASDAQ: IBB
$132.33
+$0.48 (+0.4%)
Closing price April 11, 2024
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published:
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Published:
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Published:
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Published:
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.
Published:
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus price target.
Published:
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
Published:
Even though tech stocks on average are posting far better gains that health care stocks, a fair number of health care stocks — biotechs specifically — are blowing these tech stocks out of the...
Published:
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Published:
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on the top exchange traded funds for those sectors.
Published:
Last Updated:
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Published:
Last Updated:
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Published:
Last Updated:
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Published:
Last Updated:
Merrill Lynch singled out a group in the tech sector that the firm believes will outperform going forward -- specifically, internet stocks.
Published:
Last Updated: